title: Heparin-like inhibitory activity to fibroblast growth factor-2 in wound fluids of patients with chronic skin ulcers and its modulation during wound healing.
abstract: Fibroblast growth factors are potent mitogens and angiogenic factors which play a critical role in wound healing. Fibroblast growth factors require heparan sulfates as cofactors in order to activate their cognate receptors and exert their cellular and biological effects. Heparan sulfates were extracted from wound fluids of 5 patients with chronic diabetic foot ulcers or chronic venous stasis ulcers and tested for their capacity to modulate fibroblast growth factor-receptor binding, during the course of the ulcers' resolution, until complete healing (3-8 months). Total heparan sulfates concentration measured as iduronic acid equivalents, decreased in wound fluids from 1.1 +/-0.3 microg/ml to 0.26 +/-0.1 microg/ml as wound healing progressed. These heparan sulfates exhibited a predominant inhibitory effect on fibroblast growth factor-2 binding to fibroblast growth factor receptor-1, when tested in cells deficient in cell surface heparan sulfates. During wound healing, there was a marked decrease in the relative inhibitory activity of the extracted heparan sulfates on fibroblast growth factor-2-receptor binding. Heparan sulfates extracted from chronic skin ulcers of different etiologies such as diabetic foot or chronic venous stasis ulcers showed the same pattern of alternating balance in heparan sulfates mediated activity. The presence of fibroblast growth factor inhibitory factors which possess heparin-like activity in fluids of chronic skin ulcers and their ability to modulate fibroblast growth factor-receptor activity throughout the process of wound healing, may significantly contribute to the mechanism of chronicity. Treatments to counter this inhibition may offer new possibilities for healing chronic wounds.
authors.affiliation: Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
authors.forename: Z
authors.initials: Z
authors.lastname: Landau
authors.forename: M
authors.initials: M
authors.lastname: David
authors.forename: D
authors.initials: D
authors.lastname: Aviezer
authors.forename: A
authors.initials: A
authors.lastname: Yayon
mesh_terms: D001826:Body Fluids / Q000378:metabolism; D002478:Cells, Cultured; D002908:Chronic Disease; D005347:Fibroblasts / Q000378:metabolism* / Q000502:physiology; D016523:Foot Ulcer / Q000378:metabolism; D006497:Heparan Sulfate / Q000032:analysis / Q000494:pharmacology*; D006801:Humans; D018125:Receptors, Transforming Growth Factor beta / Q000187:drug effects* / Q000378:metabolism*; D012680:Sensitivity and Specificity; D012883:Skin Ulcer / Q000378:metabolism / Q000503:physiopathology*; D014647:Varicose Ulcer / Q000378:metabolism; D014945:Wound Healing / Q000502:physiology*
chemical_list: D006497:Heparan Sulfate; D018125:Receptors, Transforming Growth Factor beta